PL346877A1 - Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid - Google Patents
Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acidInfo
- Publication number
- PL346877A1 PL346877A1 PL99346877A PL34687799A PL346877A1 PL 346877 A1 PL346877 A1 PL 346877A1 PL 99346877 A PL99346877 A PL 99346877A PL 34687799 A PL34687799 A PL 34687799A PL 346877 A1 PL346877 A1 PL 346877A1
- Authority
- PL
- Poland
- Prior art keywords
- morpholinol
- difluorophenyl
- dimethyl
- alginic acid
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10211298P | 1998-09-28 | 1998-09-28 | |
PCT/EP1999/007117 WO2000018406A1 (en) | 1998-09-28 | 1999-09-24 | Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
PL346877A1 true PL346877A1 (en) | 2002-03-11 |
Family
ID=22288187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL99346877A PL346877A1 (en) | 1998-09-28 | 1999-09-24 | Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1117407A1 (xx) |
JP (1) | JP2002525328A (xx) |
KR (1) | KR20010075385A (xx) |
CN (1) | CN1328459A (xx) |
AR (1) | AR022673A1 (xx) |
AU (1) | AU6087399A (xx) |
BR (1) | BR9914096A (xx) |
CA (1) | CA2345638A1 (xx) |
CZ (1) | CZ20011142A3 (xx) |
HU (1) | HUP0103459A2 (xx) |
IL (1) | IL142054A0 (xx) |
MA (1) | MA26693A1 (xx) |
NO (1) | NO20011555D0 (xx) |
PE (1) | PE20001087A1 (xx) |
PL (1) | PL346877A1 (xx) |
TR (1) | TR200100863T2 (xx) |
WO (1) | WO2000018406A1 (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
-
1999
- 1999-09-23 MA MA25782A patent/MA26693A1/fr unknown
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/ja active Pending
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/xx unknown
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/cs unknown
- 1999-09-24 CN CN99813675A patent/CN1328459A/zh active Pending
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/hu unknown
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Application Discontinuation
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/ko not_active Application Discontinuation
- 1999-09-24 AR ARP990104841A patent/AR022673A1/es unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/pt not_active IP Right Cessation
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 PL PL99346877A patent/PL346877A1/xx unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/xx unknown
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/es not_active Application Discontinuation
-
2001
- 2001-03-27 NO NO20011555A patent/NO20011555D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20011555L (no) | 2001-03-27 |
TR200100863T2 (tr) | 2001-07-23 |
MA26693A1 (fr) | 2004-12-20 |
KR20010075385A (ko) | 2001-08-09 |
CN1328459A (zh) | 2001-12-26 |
NO20011555D0 (no) | 2001-03-27 |
IL142054A0 (en) | 2002-03-10 |
CZ20011142A3 (cs) | 2001-09-12 |
WO2000018406A1 (en) | 2000-04-06 |
JP2002525328A (ja) | 2002-08-13 |
AR022673A1 (es) | 2002-09-04 |
BR9914096A (pt) | 2001-07-31 |
PE20001087A1 (es) | 2000-10-20 |
HUP0103459A2 (hu) | 2002-01-28 |
EP1117407A1 (en) | 2001-07-25 |
AU6087399A (en) | 2000-04-17 |
CA2345638A1 (en) | 2000-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2355854A1 (en) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | |
AU2317699A (en) | Dental restoratives | |
HUP0100950A3 (en) | Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them | |
HUP0104195A3 (en) | Vitamin d analogues, preparation thereof, pharmaceutical and cosmetic compositions containing them | |
IL172695A0 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
HK1034183A1 (en) | Galenic formulations of meloxicam for oral administration. | |
AU4338099A (en) | Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient | |
AU3216600A (en) | Analgesic compositions comprising anti-epileptic compounds and methods of using same | |
HUP0103464A3 (en) | Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them | |
HUP0203505A3 (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, and pharmaceutical compositions containing said compounds | |
AU1574900A (en) | Pharmaceutical compositions containing insulin | |
HU9802795D0 (en) | Pharmaceutical compositions containing more active components | |
HUP0103924A3 (en) | Oral pharmaceutical compositions containing buprenorphin | |
HUP0105204A3 (en) | Substituted phenethylamine derivatives and pharmaceutical compositions containing them | |
IL142534A0 (en) | Pharmaceutical compositions containing an antigen-adjuvent | |
PL349393A1 (en) | Sulphonyloxazolamines as therapeutic active ingredients | |
AU1453600A (en) | Solid oral dosage forms containing alginic acid and famotidine | |
PL346877A1 (en) | Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid | |
ZA997511B (en) | Novel heteroethynlene compounds and pharmaceutical and cosmetic compositions containing same. | |
HUP9800413A3 (en) | Fungicide composition containing 5-methyl-5-(4-phenoxyphenyl)-3-phenylamino-2,4-oxazolidinedione and triazole-derivative compound as active ingredients and use thereof | |
HUP9802716A3 (en) | Pharmaceutical composition of analgesic activity | |
IL138994A0 (en) | 2-methylpropionic acid derivatives and medicinal compositions containing the same | |
AU6524298A (en) | Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease | |
HU9800623D0 (en) | Oral application of "(+)-o-demethyl-tramadol as analgesic active component | |
HU9502509D0 (en) | Use of 1,4-dihydropyridine-3,5-dicarboxylic-acid-esters as active component of pharmaceutical compositions |